Image credit: Freepik
SK pharmteco, a leading global contract development and manufacturing organization (CDMO), and Prozomix, a pioneer in enzyme discovery and diversity, have entered a strategic partnership. This collaboration aims to integrate Prozomix’s extensive biocatalyst libraries into SK pharmteco’s small-molecule development and manufacturing services, accelerating the transition to sustainable, efficient pharmaceutical processes.
Through the partnership, SK pharmteco will gain access to Prozomix’s complete “Biocatalysis Enzyme Toolkit,” which features over 6,000 diverse native biocatalysts. This access allows SK pharmteco to utilize the enzymes and screen across its R&D centers in the U.S., Europe, and Asia, enabling the rapid identification of high-performing enzymes for complex API (Active Pharmaceutical Ingredient) synthesis.
Joerg Ahlgrimm, CEO of SK pharmteco said “Integrating Prozomix’s enzyme diversity into our global R&D and manufacturing workflow is complementary to our existing technology platforms and enables us to offer more innovative and sustainable solutions to our clients, ensuring we bring the best expertise to help our clients navigate the complexities of drug development.”
As drug molecules become more complex, using enzymes provides a greener, more selective, and cost-effective alternative to traditional chemical synthesis. By combining SK pharmteco’s expertise in small molecule API production with Prozomix’s enzyme diversity, the collaboration offers clients a smooth path from initial enzyme screening to full-scale enzyme production and drug manufacturing.
The collaboration marks a significant expansion of SK pharmteco’s technology offerings, further solidifying its position as a multi-modality partner of choice for the global biopharmaceutical industry.
